Chile collaboration is bringing surgical patients closer to having a
long-acting local anesthetic. In a randomized, double-blind trial,
patients given neosaxitoxin, a new local anesthetic derived from algae,
had significantly less postoperative pain and recovered about two days
sooner than those given the commonly used local anesthetic bupivacaine.
Based on this finding, Children's Hospital Boston, a co-investigator on
the study, has signed a collaboration agreement with biotech start-up
company Proteus SA (Santiago, Chile) to move the new anesthetic toward
clinical adoption. Tens of millions of patients have operations
requiring local anesthesia each year. Current local anesthetics act for
less than 8 hours; when they wear off, patients generally need opioid
analgesics, which cause substantial side effects, including nausea,
sedation, shallow breathing, sleepiness, constipation and itching. These
side effects often delay recovery and can result in prolonged
hospitalization. ESCIENCE
No comments:
Post a Comment